Nanjing RegeneCore's RC1416 Injection Demonstrates Positive Results in Asthma Ib Clinical Study, Initiates Phase II Preparations

Nanjing RegeneCore's self-developed RC1416 injection has shown promising progress in its Ib phase clinical study for asthma treatment. Interim data indicate favorable efficacy, safety, and tolerability profiles. Based on these positive outcomes, the RegeneCore team has decided to fully initiate preparations for Phase II clinical studies to accelerate RC1416's clinical development.

Nanjing RegeneCore Announces New Breakthrough in Brain-Penetrating Drug Delivery Technology

The blood-brain barrier (BBB) strictly regulates the passage of substances into and out of the central nervous system (CNS), playing a crucial role in preventing harmful substances from entering the brain from the bloodstream. However, it also poses a significant challenge by restricting most drugs from reaching the brain parenchyma, severely limiting the treatment of CNS disorders.

Nanjing RegeneCore RC1416 dual antibody has obtained 2 clinical trial licenses again

Recently, Nanjing RegeneCore Biotechnology Co., Ltd.'s RC1416 project has consecutively obtained Investigational New Drug (IND) approvals from the National Medical Products Administration's Center for Drug Evaluation (CDE) for indications of atopic dermatitis (AD) and chronic obstructive pulmonary disease (COPD). The expansion of these indications has further diversified the clinical application scenarios of RC1416 injection, providing better treatment options for more patients.